NASDAQ:REPL Replimune Group (REPL) News Today $18.48 -0.51 (-2.69%) (As of 06/1/2023 ET) Add Compare Share Share Today's Range$18.40▼$19.1150-Day Range$15.65▼$19.7852-Week Range$13.84▼$29.52Volume176,082 shsAverage Volume544,215 shsMarket Capitalization$1.07 billionP/E RatioN/ADividend YieldN/APrice Target$51.60 HeadlinesProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Get Replimune Group News Delivered to You Automatically Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter. Email Address REPL Media Mentions By Week REPL Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. REPL News Sentiment▼0.320.47▲Average Medical News Sentiment REPL News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. REPL Articles This Week▼72▲REPL Articles Average Week All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineReplimune to Present at the Jefferies Global Healthcare Conferencefinance.yahoo.com - June 1 at 4:57 PMReplimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Connor Clark & Lunn Investment Management Ltd.marketbeat.com - June 1 at 6:51 AMReplimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Schroder Investment Management Groupmarketbeat.com - May 31 at 7:30 AMSVB Securities Reaffirms Their Buy Rating on Replimune Group (REPL)markets.businessinsider.com - May 29 at 5:39 PMEF Hutton Reiterates Replimune Group (REPL) Buy Recommendationmsn.com - May 26 at 10:34 PMFY2024 EPS Estimates for Replimune Group, Inc. (NASDAQ:REPL) Cut by Wedbushamericanbankingnews.com - May 26 at 2:22 AMReplimune to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meetingfinance.yahoo.com - May 25 at 9:32 PMReplimune Group, Inc. (NASDAQ:REPL) Shares Purchased by Swiss National Bankmarketbeat.com - May 25 at 4:44 AMReplimune Group, Inc. (NASDAQ:REPL) Expected to Earn Q1 2024 Earnings of ($0.87) Per Shareamericanbankingnews.com - May 25 at 1:38 AMBMO Capital Keeps Their Buy Rating on Replimune Group (REPL)markets.businessinsider.com - May 23 at 8:34 AMWedbush Comments on Replimune Group, Inc.'s Q1 2024 Earnings (NASDAQ:REPL)marketbeat.com - May 23 at 5:57 AMVictory Capital Management Inc. Buys New Shares in Replimune Group, Inc. (NASDAQ:REPL)marketbeat.com - May 23 at 5:38 AMWedbush Reiterates Replimune Group (REPL) Outperform Recommendationmsn.com - May 22 at 8:24 PMReplimune Group, Inc. (NASDAQ:REPL) Given Consensus Recommendation of "Buy" by Analystsamericanbankingnews.com - May 22 at 3:40 AMJean M. Franchi Sells 11,351 Shares of Replimune Group, Inc. (NASDAQ:REPL) Stockamericanbankingnews.com - May 20 at 6:04 AMReplimune Group, Inc. (NASDAQ:REPL) CEO Philip Astley-Sparke Sells 17,902 Sharesamericanbankingnews.com - May 20 at 5:30 AMLetko Brosseau & Associates Inc. Lowers Holdings in Replimune Group, Inc. (NASDAQ:REPL)marketbeat.com - May 19 at 12:08 PMAnalysts Conflicted on These Healthcare Names: Teva Pharmaceutical (TEVA) and Replimune Group (REPL)markets.businessinsider.com - May 18 at 11:29 PMReplimune Group Chief Financial Officer Jean Franchi Resigns >REPLmarketwatch.com - May 18 at 1:27 PMRecap: Replimune Group Q4 Earningsmsn.com - May 18 at 1:27 PMReplimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - May 18 at 8:27 AMIs a Surprise Coming for Replimune (REPL) This Earnings Season?finance.yahoo.com - May 17 at 3:22 PMReplimune Group, Inc. (NASDAQ:REPL) Given Average Rating of "Buy" by Analystsmarketbeat.com - May 17 at 1:44 AMReplimune to Participate in the Piper Sandler Spring Biopharma Symposiumfinance.yahoo.com - May 9 at 12:56 PMTD Asset Management Inc Raises Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL)marketbeat.com - May 8 at 5:32 AMProShare Advisors LLC Buys Shares of 9,341 Replimune Group, Inc. (NASDAQ:REPL)marketbeat.com - May 4 at 5:00 AMReplimune Group, Inc. (NASDAQ:REPL) Shares Bought by Frazier Life Sciences Management L.P.marketbeat.com - May 1 at 5:21 AMFisher Asset Management LLC Purchases 14,826 Shares of Replimune Group, Inc. (NASDAQ:REPL)marketbeat.com - April 28 at 5:46 AMReplimune Group, Inc. (NASDAQ:REPL) Receives $51.67 Average Price Target from Brokeragesamericanbankingnews.com - April 25 at 1:32 AMReplimune Group (NASDAQ:REPL) Rating Reiterated by Piper Sandleramericanbankingnews.com - April 20 at 5:24 AMReplimune Group (REPL) Receives a Buy from Piper Sandlermarkets.businessinsider.com - April 17 at 8:05 AMReplimune Group (NASDAQ:REPL) Trading Down 3.5%americanbankingnews.com - April 12 at 8:32 AMReplimune Group, Inc. (NASDAQ:REPL) Receives Average Recommendation of "Buy" from Analystsamericanbankingnews.com - April 2 at 2:24 AMaTyr Pharma (NASDAQ:LIFE) versus Replimune Group (NASDAQ:REPL) Critical Reviewamericanbankingnews.com - April 1 at 3:58 AMDown -22% in 4 Weeks, Here's Why Replimune Group, Inc. (REPL) Looks Ripe for a Turnaroundfinance.yahoo.com - March 31 at 3:06 PMMoody Aldrich Partners LLC Buys New Shares in Replimune Group, Inc. (NASDAQ:REPL)marketbeat.com - March 31 at 2:38 PMReplimune Group, Inc. (NASDAQ:REPL) Receives Average Rating of "Buy" from Analystsmarketbeat.com - March 28 at 2:18 AMREPL Replimune Group, Inc.seekingalpha.com - March 17 at 6:48 PMReplimune Group, Inc. (NASDAQ:REPL) Shares Sold by Price T Rowe Associates Inc. MDmarketbeat.com - March 14 at 4:58 AMReplimune Group, Inc. (NASDAQ:REPL) Shares Sold by Price T Rowe Associates Inc. MDmarketbeat.com - March 14 at 4:58 AMReplimune Group, Inc. (NASDAQ:REPL) Shares Purchased by Ensign Peak Advisors Incmarketbeat.com - March 13 at 5:29 AMPoint72 Asset Management L.P. Trims Holdings in Replimune Group, Inc. (NASDAQ:REPL)marketbeat.com - March 3 at 6:01 AMReplimune Group, Inc. (NASDAQ:REPL) Receives Average Rating of "Buy" from Brokeragesmarketbeat.com - March 3 at 2:19 AMReplimune Group, Inc. (REPL) Loses -14.58% in 4 Weeks, Here's Why a Trend Reversal May be Around the Cornerfinance.yahoo.com - February 24 at 6:18 PMConnor Clark & Lunn Investment Management Ltd. Increases Stake in Replimune Group, Inc. (NASDAQ:REPL)marketbeat.com - February 22 at 5:09 AMHC Wainwright Raises Replimune Group (NASDAQ:REPL) Price Target to $50.00marketbeat.com - February 10 at 11:57 AMBarclays PLC Raises Holdings in Replimune Group, Inc. (NASDAQ:REPL)marketbeat.com - February 10 at 4:35 AMReplimune Group GAAP EPS of -$0.69 beats by $0.08msn.com - February 9 at 9:43 AMReplimune Reports Fiscal Third Quarter Financial Results and Provides Corporate Updatefinance.yahoo.com - February 9 at 9:43 AMReplimune to Present at the Virtual SVB Securities Global Biopharma Conferencefinance.yahoo.com - February 7 at 9:23 AM Get Replimune Group News Delivered to You Automatically Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Scilex News ImmunityBio News Inhibrx News Valneva News Adaptive Biotechnologies News ADMA Biologics News Exscientia News Sana Biotechnology News REGENXBIO News Allogene Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:REPL) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.